OptiPin
Cerebrolysin: uses, dosing & the facts
A nootropic peptide complex derived from pig brain tissue containing neurotrophic factors. Supports brain health, cognitive function, and neuroprotection. This is an evidence-graded reference – what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • Cerebrolysin – Nootropic / cognitive. A nootropic peptide complex derived from pig brain tissue containing neurotrophic factors.
- • Commonly used for cognitive enhancement, neuroprotection, brain injury recovery.
- • Half-life: Varies.
- • Status: Research use only · not FDA-approved – an educational reference, not a dose protocol or sourcing advice.
What Cerebrolysin is
A nootropic peptide complex derived from pig brain tissue containing neurotrophic factors. Supports brain health, cognitive function, and neuroprotection.
What Cerebrolysin is used for
- • Cognitive enhancement
- • Neuroprotection
- • Brain injury recovery
- • Alzheimer's and dementia support
- • Stroke recovery
- • Memory improvement
- • Mental clarity and focus
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | Dosed by volume, not by weight. The standard solution is 215.2mg/mL, so 1mL is about 215mg. Manufacturer daily ranges are 10–30mL for Alzheimer's or vascular dementia and 20–50mL for stroke or traumatic brain injury. Cognitive-enhancement use is commonly 1–5mL daily. Intramuscular is capped at 5mL per injection and IV push at 10mL; larger daily amounts are given as a diluted IV infusion. |
Presented as commonly-reported patterns for information only – not a dose recommendation. Cerebrolysin dosing is a decision for a qualified clinician.
Reconstitution
Pre-formulated solution at 215.2mg/mL in ready-to-use ampoules and vials (commonly 1, 2, 5, 10, 20 and 30mL). No reconstitution needed. Single use only: do not store or reuse an opened ampoule. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.
Half-life & cycling
Half-life: Varies. Half-life drives dosing frequency and how quickly the compound clears – see it plotted on the Cerebrolysin half-life calculator.
Cycling
Manufacturer cycles for dementia are 5 days per week for 4 weeks, repeated 2–4 times per year. Stroke courses run 10–21 consecutive days and traumatic brain injury 7–30 days. Continuous use may lead to tolerance.
Side effects & warnings
- an injection site that turns red, hot or hard, spreads, weeps, or comes with a fever – same-day medical care – research-grade material carries no sterility guarantee, so abscess and cellulitis are the documented consequence
- swelling of the lips, tongue or throat, trouble breathing, or widespread hives after a dose – emergency care
- a new or sharply worsening mood change, or any thought of harming yourself – urgent medical help; stop the compound
- • Generally well-tolerated
- • Possible mild headache initially
- • Mild injection site reactions
- • Rare dizziness or nausea
Research use only. The manufacturer approves intramuscular and intravenous administration only, not subcutaneous. Intranasal use is not an established route: standard ampoules contain no absorption enhancers and nasal absorption is poor. Requires cycling to prevent tolerance. Used in many countries for stroke and brain injury recovery, though a meta-analysis of acute ischemic stroke trials did not show a significant benefit.
Tracking Cerebrolysin in OptiPin
If you're tracking a Cerebrolysin protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math – all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math – all on-device.
Download on the App StoreFAQ
What is Cerebrolysin?
A nootropic peptide complex derived from pig brain tissue containing neurotrophic factors. Supports brain health, cognitive function, and neuroprotection.
What is Cerebrolysin used for?
Commonly discussed uses include: cognitive enhancement, neuroprotection, brain injury recovery, alzheimer's and dementia support, stroke recovery, memory improvement, mental clarity and focus. These are reported uses, not proven outcomes or a recommendation.
How is Cerebrolysin dosed?
Commonly reported dosing: Injectable – Dosed by volume, not by weight. The standard solution is 215.2mg/mL, so 1mL is about 215mg. Manufacturer daily ranges are 10–30mL for Alzheimer's or vascular dementia and 20–50mL for stroke or traumatic brain injury. Cognitive-enhancement use is commonly 1–5mL daily. Intramuscular is capped at 5mL per injection and IV push at 10mL; larger daily amounts are given as a diluted IV infusion.. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation – Cerebrolysin is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute Cerebrolysin?
Pre-formulated solution at 215.2mg/mL in ready-to-use ampoules and vials (commonly 1, 2, 5, 10, 20 and 30mL). No reconstitution needed. Single use only: do not store or reuse an opened ampoule. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is Cerebrolysin's half-life?
Varies. Half-life shapes how often it is dosed and how quickly it clears.
What are Cerebrolysin's side effects?
Reported effects include: generally well-tolerated, possible mild headache initially, mild injection site reactions, rare dizziness or nausea. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for Cerebrolysin on PubMed (entry point to the primary evidence base, not a specific citation).
- Cerebrolysin on ClinicalTrials.gov – registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide – categories, evidence grading, and how to run a protocol honestly.
Related
Noopept · 9-Me-BC · semax-selank · Reconstitution calculator · All peptides